Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43874   clinical trials with a EudraCT protocol, of which   7294   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-003285-12
    Sponsor's Protocol Code Number:BGB-11417-103
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-10-19
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-003285-12
    A.3Full title of the trial
    A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
    Estudio de fase Ib/II, abierto, de búsqueda de dosis y expansión del inhibidor de Bcl-2 BGB-11417 en pacientes con neoplasias malignas mieloides
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study of BGB-11417 in Patients with Myeloid Malignancies
    Estudio de BGB-11417 en pacientes neoplasias malignas mieloides
    A.3.2Name or abbreviated title of the trial where available
    BGB-11417-103: a Phase 1b/2 study of BGB-11417 in patients with myeloid malignancies
    BGB-11417-103: Estudio de fase Ib/II de BGB-11417 en pacientes neoplasias malignas mieloides
    A.4.1Sponsor's protocol code numberBGB-11417-103
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04771130
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBeiGene, Ltd.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBeiGene, Ltd.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBeiGene Ltd.
    B.5.2Functional name of contact pointBeiGene Clinical Support
    B.5.3 Address:
    B.5.3.1Street AddressUSA
    B.5.3.2Town/ cityUSA
    B.5.3.3Post codeUSA
    B.5.3.4CountryUnited States
    B.5.6E-mailclinicaltrials@beigene.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBGB-11417
    D.3.2Product code BGB-11417
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot established
    D.3.9.1CAS number 2383086-06-2
    D.3.9.2Current sponsor codeBGB-11417
    D.3.9.3Other descriptive nameBGB-11417
    D.3.9.4EV Substance CodeAS2
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBGB-11417
    D.3.2Product code BGB-11417
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot established
    D.3.9.1CAS number 2383086-06-2
    D.3.9.2Current sponsor codeBGB-11417
    D.3.9.3Other descriptive nameBGB-11417
    D.3.9.4EV Substance CodeAS2
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBGB-11417
    D.3.2Product code BGB-11417
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot established
    D.3.9.1CAS number 2383086-06-2
    D.3.9.2Current sponsor codeBGB-11417
    D.3.9.3Other descriptive nameBGB-11417
    D.3.9.4EV Substance CodeAS2
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number80
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAzacitidine
    D.3.4Pharmaceutical form Powder for suspension for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAzacitidine
    D.3.9.1CAS number 320-67-2
    D.3.9.4EV Substance CodeSUB05624MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/m2 milligram(s)/square meter
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number75
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Myeloid malignancies (acute myeloid leukemia [AML], myelodysplastic syndromes [MDS], and myelodysplastic syndrome/myeloproliferative neoplasms [MDS/MPN])
    Neoplasias malignas mieloides ( leucemia mieloide aguda [LMA], síndromes mielodisplásicos [SMD], y síndrome mielodisplásico/neoplasias mieloproliferativas [SMD/NMP])
    E.1.1.1Medical condition in easily understood language
    Cancers of the blood (acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic syndrome/myeloproliferative neoplasms
    Cánceres de la sangre ( leucemia mieloide aguda, síndromes mielodisplásicos y síndrome mielodisplásico/neoplasias mieloproliferativas
    E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Part 1 (dose regimen finding) and Part 2 (safety expansion)
    • To determine the safety and tolerability of BGB-11417 in combination with azacitidine in patients with myeloid malignancies
    • To select the dose regimens of BGB-11417 in combination with azacitidine to be evaluated in Part 2 (in Part 1 only)
    • To determine the recommended Phase 2 dose (RP2D) of BGB-11417 in combination with azacitidine to be evaluated in Part 3

    Part 3 (efficacy expansion)
    • To evaluate the antileukemic activity of BGB-11417 in combination with azacitidine as measured by response rates
    • To evaluate the effect of posaconazole on the pharmacokinetics of BGB-11417 when coadministered in a drug-drug interaction (DDI) cohort
    (Note: the DDI evaluation with posaconazole will not be conducted in Europe)
    Parte 1 (determinación de la pauta posológica) y parte 2 (expansión de seguridad)
    • Determinar la seguridad y tolerabilidad de BGB‐11417 en combinación con azacitidina en pacientes con neoplasias malignas mieloides.
    • Seleccionar las pautas posológicas de BGB-11417 en combinación con azacitidina que se evaluarán en la parte 2 (solo en la parte 1).
    • Determinar la dosis recomendada para la fase II (DRP2) de BGB‐11417 en combinación con azacitidina que se evaluará en la parte 3.

    Parte 3 (Expansión de eficacia)

    • Evaluar la actividad antileucémica de BGB‐11417 en combinación con azacitidina determinada mediante las tasas de respuesta.
    • Evaluar el efecto de posaconazol en la farmacocinética de BGB-11417 cuando se administra de forma concomitante en una cohorte de interacción farmacológica (IF).
    E.2.2Secondary objectives of the trial
    Part 1 (dose regimen finding) and Part 2 (safety expansion)
    • To evaluate the antileukemic activity of BGB-11417 in combination with azacitidine as measured by response rates
    • To assess the pharmacokinetics (PK) of BGB-11417 and azacitidine when given in combination

    Part 3 (efficacy expansion)
    • To evaluate the safety and tolerability of the selected BGB-11417 dose regimen in combination with azacitidine
    • To evaluate the antileukemic activity of BGB-11417 in combination with azacitidine as measured by duration of responses, time to responses, and additional time-to-event outcomes
    • To assess the pharmacokinetics of BGB-11417 in combination with azacitidine
    • To evaluate the safety of BGB-11417 when coadministered with posaconazole in a DDI cohort
    (Note: the DDI evaluation with posaconazole will not be conducted in Europe)
    Parte 1 (determinación de la pauta posológica) y parte 2 (expansión de seguridad)
    • Evaluar la actividad antileucémica de BGB‐11417 en combinación con azacitidina determinada mediante las tasas de respuesta.
    • Evaluar la farmacocinética (FC) de BGB‐11417 y azacitidina cuando se administran en combinación.

    Parte 3 (Expansión de eficacia)
    • Evaluar la seguridad y tolerabilidad de la pauta posológica seleccionada de BGB‐11417 en combinación con azacitidina.
    • Evaluar la actividad antileucémica de BGB‐11417 en combinación con azacitidina determinada a través de la duración de las respuestas, el tiempo hasta las respuestas y los resultados adicionales de tiempo hasta el acontecimiento.
    • Evaluar la farmacocinética de BGB‐11417 y azacitidina cuando se administran en combinación.
    • Evaluar la seguridad de BGB-11417 administrado concomitantemente con posaconazol en una cohorte de IF.
    (Nota: La evaluación IF con posaconazol no será realizada en Europa)
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Confirmed diagnosis of one of the following by 2016 World Health Organization criteria:
    • acute myeloid leukemia (AML), nonacute promyelocytic leukemia;
    • myelodysplastic syndrome (MDS); or
    • myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN)
    2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
    3. Adequate organ function defined as:
    • Creatinine clearance ≥ 50 milliliters/minute (mL/min)
    • Adequate liver function
    4. Life expectancy of > 12 weeks.
    5. Ability to comply with the requirements of the study.
    Note: other protocol-defined inclusion criteria may apply.
    1. Diagnóstico confirmado de una de los siguientes criterios de 2016 de la Organización Mundial de la salud:
    • Leucemia mieloide aguda (LMA), leucemia promielocítica no aguda;
    • síndrome mielodisplásico (SMD); o
    • síndrome mielodisplásico/neoplasias mieloproliferativas [SMD/NMP]
    2. Estado General de 0 a 2 según la escala Eastern Cooperative Oncology Group (ECOG)
    3. Con una función orgánica adecuada definida como:
    • Aclaramiento de Creatinina ≥ 50 mililitros/minuto (mL/min)
    • Función hepática adecuada.
    4. Esperanza de vida mayor de 12 semanas.
    5. Capacidad de cumplir con los requisitos del estudio.
    Nota: podrán aplicar otros criterios de inclusión definidos por protocolo.
    E.4Principal exclusion criteria
    1. A diagnosis of acute promyelocytic leukemia.
    2. Prior malignancy within the past 2 years, except for curatively treated localized skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer.
    3. Antecedent MPN including myelofibrosis, essential thrombocytosis, polycythemia vera, or chronic myelogenous leukemia with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation.
    4. Prior therapy with a B-cell lymphoma-2 inhibitor or azacitidine.
    5. Known central nervous system involvement by leukemia.
    Note: other protocol-defined exclusion criteria may apply.
    1. Diagnóstico de leucemia promielocítica aguda.
    2. Neoplasias previas en los 2 años anteriores, excepto cáncer de piel localizado tratado hasta curación, cáncer superficial de vejiga, carcinoma in situ de cérvix o mama, o cáncer de próstata localizado con una puntuación de Gleason ≤6.
    3. Antecedentes de NMP incluidos mielofibrosis, trombocitosis esencial, policitemia vera, o leucemia mielógena crónica con o sin translocación BCR-ABL1 y LMA con translocación BCR-ABL1.
    4. Terapia previa con un inhibidor de células B2 de linfoma o azacitidina.
    5. Afectación del Sistema nervioso central conocida por la leucemia.
    Nota: podrán aplicar otros criterios de exclusión definidos por protocolo.
    E.5 End points
    E.5.1Primary end point(s)
    Part 1 (dose regimen finding) and Part 2 (safety expansion)
    • Safety and tolerability of BGB-11417 in combination with azacitidine as assessed by dose-limiting toxicities (DLTs)and the incidence, timing, and severity of treatment-emergent adverse events (TEAEs), according to NCI-CTCAE v5.0.

    Part 3 (efficacy expansion)
    • For AML:
    - complete remission (CR) + complete remission with partial hematologic recovery (CRh) rate;
    - In the DDI cohort: PK endpoints of BGB-11417, including but not limited to area under the curve (AUC) and maximum plasma concentration (Cmax), derived from the plasma concentration-time profiles
    • For MDS: modified overall response (mOR) rate, including CR, marrow complete remission (mCR), and partial remission (PR).
    Parte 1 (determinación de la pauta posológica) y parte 2 (expansión de seguridad)
    • Seguridad y tolerabilidad de BGB-11417 en combinación con azacitidina evaluada mediante las toxicidades limitantes de dosis (TLD) y la incidencia, el momento y la gravedad de los acontecimientos adversos surgidos durante el tratamiento (AAST), de acuerdo con los criterios NCI-CTCAE v5.0.

    Parte 3 (Expansión de eficacia)
    • Para LMA:
    -Tasa de remisión completa (RC) + tasa de remisión completa con recuperación hematológica parcial (RCh);
    - En la cohorte IF : los criterios de valoración FC de BGB-11417, incluidos pero no limitados a el área bajo la curva (ABC) y la concentración plasmática máxima observada (Cmáx), derivadas de los perfiles de concentración plasmática frente al tiempo .

    • Para SMD: tasa de respuesta global modificada (RGm), incluidas RC, remisión completa de médula (RCm) y remisión parcial (RP).
    E.5.1.1Timepoint(s) of evaluation of this end point
    Throughout the study.
    A lo largo del estudio
    E.5.2Secondary end point(s)
    Part 1 (dose regimen finding) and Part 2 (safety expansion)

    For AML:
    • CR + morphologic complete remission with partial hematologic recovery (CRh) rate.

    For MDS:
    • Modified overall response (mOR) rate. mOR is defined as achieving a CR, marrow complete remission (mCR), or partial remission (PR) at any time point during the study per modified IWG 2006 criteria for MDS/MPN (Cheson et al 2006)

    Secondary pharmacokinetic (PK) endpoints for both AML and MDS:
    • Derived PK parameters, including:
    − For azacitidine: maximum observed plasma concentration (Cmax), area under plasma concentration-time curve (AUC0-t, AUC0-∞), half-life (t1/2), apparent total clearance of drug from plasma (CL/F), and apparent volume of distribution (Vz/F) as appropriate;
    − For BGB-11417: AUClast,ss, Cmax,ss, steady-state trough plasma concentration (Ctrough,ss) and tmax,ss.

    Part 3 (efficacy expansion)

    For AML:
    • CR rate;
    • CR + CR with incomplete hematologic recovery (CRi) rate;
    • ORR (CR + CRi + PR + morphologic leukemia-free state [MLFS]);
    • Duration of response of CR, CR + CRi, OR and CR + CRh;
    • Time to response (TTR) of CR, CR + CRi, OR and CR + CRh;
    • Event-free survival (EFS);
    • Overall survival (OS).

    For MDS:
    • CR rate;
    • Hematological improvement – erythroid (HI-E), as per IWG 2018 criteria;
    • Hematological improvement – platelet (HI-P), as per IWG 2018 criteria;
    • Hematological improvement – neutrophil (HI-N), as per IWG 2018 criteria;
    • Transfusion independence (for at least consecutive 56-day post-baseline);
    • EFS;
    • OS.

    Safety endpoints for both AML and MDS:
    • Safety and tolerability of BGB-11417 in combination with azacitidine or posaconazole as assessed by the incidence, timing, and severity of TEAEs, according to NCI-CTCAE v5.0.
    Parte 1 (determinación de la pauta posológica) y parte 2 (expansión de seguridad)
    Para LMA:
    • Tasa de RC + Tasa de remisión completa morfológica con recuperación parcial hematológica (RCh).

    Para SMD:
    • Tasa de Respuesta Global Modificada (RGm). RGm se define como alcanzar una RP , remisión completa de médula (RCm), o remisión parcial (RP) en cualquier momento durante el estudio según los criterios modificados IWG 2006 para SMD/NMP (Cheson et al 2006)

    Criterios de valoración secundarios farmacocinéticos (FC) para ambos LMA y MDS:
    Parámetros derivados de FC, incluidos:
    - Para azacitidina: Concentración máxima observada de plasma (Cmáx), área bajo la curva de concentración de plasma-tiempo (ABC-t, ABC-∞), vida media (t1/2), aclaramiento total aparente del fármaco en el plasma (Ac/F), y volumen de distribución aparente (Vz/F) como corresponde.
    - Para BGB-11417: AUClast,ee, Cmax,ee, concentración en estado estacionario por plasma ( Cpee) y tmax,ee.

    Parte 3 (Expansión de eficacia)
    Para LMA:
    • Tasa RC;
    • Tasa RC + Tasa RC con recuperación hematológica incompleta (RCi);
    • TRG (RC + RCi + RP + estado morfológico libre de leucemia [EMLL);
    • Duración de la respuesta de RC, RC + RCi, RG and RC + RCh;
    • Tiempo hasta respuesta (THR) de RC, RC + RCi, RG and RC + RCh;
    • Supervivencia libre de eventos (SLE);
    • Supervivencia Global (SG).
    For SMD:
    • Tasa de RC;
    • Mejora Hematológica – Eritrocitos (ME-E), según los criterios IWG 2018;
    • Mejora Hematológica – Plaquetas (ME-P), según los criterios IWG 2018;
    • Mejora Hematológica – Neutrófilos (ME-N), según los criterios IWG 2018;
    • Independencia de Transfusiones (por lo menos por 56 días consecutivos después de basal);
    • SLE;
    • SG.
    Objetivos de seguridad para ambos LMA y SMD:
    • Seguridad y Tolerabilidad de BGB-11417 en combinación con azacitidina o posaconazol evaluado por la incidencia el momento y la gravedad de los acontecimientos adversos surgidos durante el tratamiento (AAST), de acuerdo con los criterios NCI-CTCAE v5.0.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Throughout the study.
    A lo largo del estudio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    Dose finding and expansion study
    Estudio de búsqueda de dosis y expansión
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA4
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    China
    New Zealand
    United States
    Germany
    Spain
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    (Note: includes long-term and survival follow-up which may be conducted via telephone)
    UVUP
    (Nota: incluye seguimientos a largo plazo y de supervivencia que podrían ser realizados por teléfono)
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.1.1Number of subjects for this age range: 0
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.2.1Number of subjects for this age range: 0
    F.1.1.3Newborns (0-27 days) No
    F.1.1.3.1Number of subjects for this age range: 0
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.4.1Number of subjects for this age range: 0
    F.1.1.5Children (2-11years) No
    F.1.1.5.1Number of subjects for this age range: 0
    F.1.1.6Adolescents (12-17 years) No
    F.1.1.6.1Number of subjects for this age range: 0
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 11
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 99
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others Yes
    F.3.3.7.1Details of other specific vulnerable populations
    Patients with incurable diseases
    Pacientes con enfermedades incurables
    F.4 Planned number of subjects to be included
    F.4.1In the member state8
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 16
    F.4.2.2In the whole clinical trial 110
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    At the time this study ends, patients who may continue to benefit from the study treatment in the opinion of the investigator will be offered access to a long-term extension study if one is available.
    En el momento en que el estudio acabe, a los pacientes que puedan continuar beneficiándose del tratamiento del estudio, según el criterio del investigador, se les ofrecerá el acceso a un estudio de extensión a largo plazo si hay alguno disponible.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-02-03
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-10-20
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 15 15:08:52 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA